ZymoGenetics ZymoGenetics has focused on
the discovery, development, and commercialization of therapeutic proteins. Thanks
to a robust discovery program, promising drug pipeline and strong development
capabilities, ZymoGenetics is an emerging leader among biotherapeutic companies.
The company has two products in advanced stage developement: rhThrombin and rFactor
XIII ZymoGenetics has also participated in the discovery or development
of five recombinant protein products marketed by other companies for the treatment
of various diseases, including diabetes, hemophilia, diabetic ulcer, gastrointestinal
motility and severe hypoglycemia in diabetic patients treated with insulin and
myocardial infarction or heart attacks.
More
on
Zymogenetics Key
Statistics for Zymogentics
Basic
Chart for Zymogenetics